EU Funds Stem Cell Technologies for Heart Repair – Eppendorf is Project Partner
Kempf et al., 2014, 2015
In the context of this EU project, DASGIP GmbH, an Eppendorf company, and the Eppendorf AG Bioprocess Center, will develop bioreactor solutions designed especially for the cultivation of hiPSCs in large scales. “We are pleased to have the Eppendorf Bioprocess Center in the TECHNOBEAT project team. In a long-standing cooperation we already have successfully developed bioreactors for the cultivation of 100 mL hiPSCs”, states Dr. Robert Zweigerdt, Principal Investigator at Hannover Medical School, Germany and TECHNOBEAT coordinator. “Now, the exciting challenge is to adapt the existing product design to the needs of stem cell cultivation in a larger volume of 1 L”, annotates Katharina Kinast, responsible Product Manager Bioprocess at Eppendorf. Development engineers and product managers at Eppendorf will create novel impeller and vessel designs to optimize hiPSCs culture mixing and shear characteristics. System-integrated filtering technology will be engineered. Holographic microscopy (industry partner Ovizio Imaging Systems NV/SA, Belgium) will be integrated as well. According to Katharina Kinast this will “altogether enable tight control and real-time monitoring of cell aggregate formation”. With its experience in polymer production and bioreactor design, Eppendorf will further contribute to establishing a GMP-conform hiPSC production process using single-use bioreactor technology.
TECHNOBEAT can provide groundbreaking findings and methods that may revolutionize cell-based heart therapies. „In the future, the microtissues may be grown outside the body in bioreactors and then injected into the patients damaged heart as a cell implant for curative treatment“, outlines Robert Zweigerdt. “Hundreds of patients with cardiac diseases waiting for an organ transplant may benefit from this technology.”
The pan-European TECHNOBEAT project builds an integrated and application-oriented research approach. For the first time, the consortium combines technologies enabling the mass production of stem cells under defined quality criteria, a strategy for growth of implantable microtissue, methods for evaluation of implant success in mammals as well as designated clinical expertise in cardiology, cardiac surgery, and multimodal imaging.
The project is funded for a period of four years. Apart from the Hannover Medical School and Eppendorf the following Institutions and companies are partnering the project: the Medical Centers at the universities of Leiden and Utrecht, the Netherlands, the University of Sheffield, UK, the Paracelsus Medical University, Austria and the industrial partners Ovizio Imaging Systems NV/SA, Belgium and Kadimastem Ltd., Israel.
Most read news
Other news from the department science
These products might interest you
Biostat STR by Sartorius
Biostat STR Generation 3 Bioreactors
Engineered for Ultimate Upstream Performance
Ambr® 250 HT Consumables by Sartorius
Efficient bioprocesses with single-use bioreactors
Minimise cleaning effort and maximise flexibility for cell and microbial cultures
Ambr® 250 Modular by Sartorius
Mini bioreactors for cell and gene therapies with high scalability
Maximise your process development with reliable single-use vessels
Brooks Instrument SLA Biotech-Serie by Brooks Instrument
Control bioprocesses efficiently and precisely with flow controllers for biotechnology applications
The SLA Biotech series has been developed specifically for the requirements in bioprocesses
Flexcell Systems by Dunn
Flexcell Cell Stretching Bioreactors for Life Science Research
Used in over 1300 laboratories worldwide, and cited in over 4000 research publications
SLAMf Biotech-Serie Massendurchflussregler by Brooks Instrument
SLAMf Mass Flow Controllers Designed Specifically for Biotech (IP66 / NEMA 4X)
Special equipment for biotech process plants, suitable for splash water and high-pressure cleaning
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.